Streamlining Biomanufacturing of Personalised Cancer Immunotherapies with Synthetic DNA
13 October 2025 | By
A Synthetic DNA Approach for Speed, Scale & Flexibility
List view / Grid view
13 October 2025 | By
A Synthetic DNA Approach for Speed, Scale & Flexibility
The global high-content screening (HCS) software and services market accounted for over $500 million in 2017 and is expected to reach approximately $1.4 billion by 2026, increasing at a compound annual growth rate of more than 11%, says Jeff McMillan, Senior Product Manager Imaging, Molecular Devices.
This webinar focused on a recent study evaluating a cohort of head and neck squamous cell carcinoma (HNSCC) patient tumours treated with anti-PD1 using CANscript™.
The Nobel Prize-winning observations and discoveries of John B. Gurdon and Shinya Yamanaka have ignited an explosion of excitement around the potential use of stem cells in research and treatment of human disease.
This webinar, supported by Tecan, focused on the automated assessment of liver and cardiac toxicities in lead optimisation, using biochemical and human iPS cell assays.
Human primary hepatocytes (hpheps) are the gold standard for in vitro evaluation of drug metabolism, drug-drug interactions, and metabolic disease research. However, hpheps don’t survive in standard 2D culture for very long – no longer than two or three days.
For most people, traditional High-Throughput Screening (HTS) represents large automation rigs and large libraries of small molecules screened against drug targets, however, the development of biological therapeutics has been gaining considerable pace for many reasons.
The General Data Protection Regulation (GDPR) is a new set of EU rules governing how a company manages, protects and administers personal data. Whether you are a subscriber, author, advertiser or supplier to our journal, we may hold information about you and we need to keep it private and secure.
Despite their vast therapeutic potential in such areas as cell therapy and tissue engineering, stem cells have yet to live up to their original hype and demonstrate widespread clinical success.
The demand for new therapeutics is driving efforts to discover novel antibodies and harness their power in both biologics and adoptive cell therapy areas.
For the next generation of cell biologists, 3D cell culture and analysis has opened doors to taking applied research one step further.
Advances in genomics and structural biology are providing drug discovery scientists with more biological targets to prosecute, and greater information about each one.
Regenerative medicine has emerged as one of the major areas of modern medical therapy. Its primary objective is to restore or establish normal function through the regeneration or replacement of diseased cells, tissues or entire organs. There are a variety of methods and approaches by which this can be achieved.…
Sometimes the difference between identifying a partial or super agonist is only the time point at which the binding reaction is measured.
The pursuit of improved R&D productivity rates coupled with decreased cycle times has dominated pharmaceutical discourse in recent years.
Target the genes that matter for efficient sequencing and analysis with custom-targeted gene panels.